{
    "code": "02023264",
    "url": "http:\/\/www.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02023264",
    "time": "2017-05-05 03:23:42",
    "許可證字號": "衛署藥輸字第023264號",
    "註銷狀態": "已註銷",
    "註銷日期": "106\/04\/18",
    "註銷理由": "許可證已逾有效期",
    "有效日期": "105\/08\/20",
    "發證日期": "90\/08\/20",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA00202326402",
    "中文品名": "益護爾凍晶注射劑",
    "英文品名": "ETHYOL LYOPHILIZED POWDER FOR INJECTION",
    "適應症": "本品用於減少末期卵巢癌或非小細胞癌（ＮＯＮ－ＳＭＡＬＬ　ＣＥＬＬ　ＬＵＮＧ　ＣＡＮＣＥＲ）病患接受ＣＩＳＰＬＡＴＩＮ多劑量給藥治療引起的累積性腎毒性，及用於減低因接受包含耳下腺（腮腺）在內之局部放射線標準療程治療的頭頸癌病患引起的中度至嚴重度口乾燥症。",
    "劑型": "243凍晶注射劑",
    "包裝": "Reconstituted solution:50mg\/ml.375公絲, 500公絲小瓶裝 各100支以下盒裝",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "主成分略述": [
        "AMIFOSTINE"
    ],
    "限制項目": "02輸　入 1Q不得輸入",
    "申請商名稱": "0929301100  美商默沙東藥廠股份有限公司台灣分公司",
    "主製造廠": {
        "主製造廠": "",
        "製造廠名稱": "F170043000  MEDIMMUNE PHARMA B.V.",
        "製造廠廠址": "LAGELANDSEWEG 78 6545 CG NIJMEGEN THE NETHERLANDS",
        "製造廠公司地址": "",
        "": ""
    },
    "CCC號列": "30049099904 其他醫藥製劑〈不包括第３００２、３００５或３００６節所列者〉包含經混合或未混合產品供治療或預防疾病用，具有劑量（包括經皮給藥形態者）或零售包裝式樣者Other medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses,put up in measured doses or in forms or packings for retail sale",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "9200092400",
            "成分名稱": "AMIFOSTINE",
            "含量描述": "",
            "含量": "375.0000000000",
            "單位": "MG"
        },
        {
            "成分類別": "主成分",
            "成分代碼": "9200092400",
            "成分名稱": "AMIFOSTINE",
            "含量描述": "",
            "含量": "500.0000000000",
            "單位": "MG"
        }
    ]
}